Sean J Iwamoto
Overview
Explore the profile of Sean J Iwamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Misakian A, Kelley C, Sullivan E, Chang J, Singh G, Kokosa S, et al.
J Clin Endocrinol Metab
. 2025 Jan;
PMID: 39797602
Context: Guidelines for use of injectable estradiol esters (valerate [EV] and cypionate [EC]) among transgender and gender diverse (TGD) individuals designated male at birth vary considerably, with many providers noting...
2.
Rothman M, Hamnvik O, Davidge-Pitts C, Safer J, Ariel D, Tangpricha V, et al.
Transgend Health
. 2024 Dec;
9(6):463-465.
PMID: 39735380
Injectable estrogens are options for gender-affirming hormone therapy per guidelines, which suggest intramuscular dosages of 5-30 mg every 2 weeks or 2-10 mg weekly with estradiol cypionate or valerate interchangeably....
3.
Iwamoto S, Moreau K
Exerc Sport Sci Rev
. 2024 Sep;
52(4):115-116.
PMID: 39248634
No abstract available.
4.
Rothman M, Ariel D, Kelley C, Hamnvik O, Abramowitz J, Irwig M, et al.
Endocr Pract
. 2024 May;
30(9):870-878.
PMID: 38782202
Objective: Feminizing gender-affirming hormone therapy is the mainstay of treatment for many transgender and gender diverse people. Injectable estradiol preparations are recommended by the World Professional Association for Transgender Health...
5.
Iwamoto S, Rice J, Moreau K, Cornier M, Wierman M, Mancuso M, et al.
J Clin Transl Endocrinol
. 2024 May;
36:100348.
PMID: 38756206
Introduction: Feminizing and masculinizing gender-affirming hormone therapy (fGAHT, mGAHT) results in bone mineral density (BMD) maintenance or improvement over time in transgender and gender diverse (TGD) adults. Mostly European TGD...
6.
Taormina J, Cordoba Kissee M, Brownstone L, Grimstad F, Morrison S, Hendrixson A, et al.
J Clin Endocrinol Metab
. 2024 Apr;
109(9):2389-2399.
PMID: 38584330
Body mass index (BMI) requirements for gender-affirming surgeries (GAS) present an obstacle to gender transition for many transgender and gender diverse (TGD) people. Furthermore, TGD people have unique barriers and...
7.
Harrison D, Prada F, Nokoff N, Iwamoto S, Pastor T, Jacobsen R, et al.
J Am Heart Assoc
. 2024 Jan;
13(3):e031004.
PMID: 38293963
Background: Transgender and gender diverse (TGD) individuals and long-term survivors with adult congenital heart disease (ACHD) are both growing populations with specialized needs. No studies assess temporal trends or evaluate...
8.
Iwamoto S, Rothman M, TSjoen G, Defreyne J
J Clin Endocrinol Metab
. 2023 Sep;
109(2):592-602.
PMID: 37683089
While endocrinologists continue to initiate gender-affirming hormone therapy (GAHT) in healthy transgender and gender diverse (TGD) patients, they may also encounter more TGD patients in their clinics with complex medical...
9.
Hoffner-Heinike A, Iwamoto S, Saxon D, Cogdall N, Davies R, Lee R, et al.
Telemed J E Health
. 2023 Jul;
30(2):430-437.
PMID: 37499094
Extension for Community Health Outcomes (ECHO) is a model of continuing medical education meant to connect academic medical center-based specialists with community providers to increase capacity in managing complex health...
10.
Taormina J, Iwamoto S
Int J Obes (Lond)
. 2023 Jul;
47(9):761-763.
PMID: 37414875
Transgender and gender diverse (TGD) adults are more likely to have obesity compared to cisgender peers. Based on surveys, the TGD population experiences disparities in healthy lifestyle behaviors (e.g., physical...